Skip to main content
. 2019 Jul 11;11(7):970. doi: 10.3390/cancers11070970

Table 3.

Summary of random effect meta-analyses for the association between miR-221 overexpression and overall survival of cancer patients.

Study Groups Studies Included Test of Association Test of Heterogeneity
HR (95% CI) p-Value I2% p-Value
All studies 25 1.48 (1.14–1.93) 0.003 75 <0.001
Ethnicity
Asian 18 1.67 (1.30–2.14) <0.001 62 <0.001
Mostly Caucasian 5 1.30 (0.69–2.44) 0.410 75 0.003
Mixed 2 0.64 (0.05–7.72) 0.723 94 <0.001
Type of cancer
Liver 5 1.98 (1.51–2.60) <0.001 0 0.698
Gastro-intestinal 7 1.29 (0.68–2.43) 0.434 83 <0.001
Neurological 6 1.56 (0.98–2.48) 0.062 77 <0.001
Urogenital 2 0.72 (0.18–2.90) 0.638 70 0.069
NSCLC 2 1.92 (1.31–2.81) 0.001 0 0.602
Other 3 1.51 (0.45–5.01) 0.504 84 0.002
No pre-treatment # 14 1.84 (1.56–2.17) <0.001 0 0.813
Sample detected
Fresh/frozen tissue 12 1.54 (1.05–2.28) 0.028 70 <0.001
FFPE 10 1.68 (1.20–2.36) 0.003 66 0.002
Sample size *
≥100 9 1.27 (0.78–2.08) 0.332 86 <0.001
<100 16 1.62 (1.21–2.18) 0.001 58 0.002
Survival analysis
Univariate 9 1.54 (1.07–2.21) 0.020 55 0.024
Multivariate 16 1.46 (1.02–2.09) 0.039 81 <0.001
NOS score
≥7 19 1.61 (1.20–2.16) 0.002 71 <0.001
<7 6 1.17 (0.65–2.11) 0.604 84 <0.001

* Number of cancer patients; # Patients without pre-operative anticancer treatment; FFPE, formalin-fixed, paraffin-embedded tissue; HR, hazard ratio; NOS, Newcastle–Ottawa Scale; NSCLC, non-small cell lung cancer.